Canaccord Genuity Group Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Key Points

• Canaccord Genuity raised Heartflow’s price target to $69 from $56 and maintained a “buy” rating, implying 15.15% upside from the prior close. Analysts’ consensus rating is “Moderate Buy,” with an average target of $56.25.
• Heartflow’s third-quarter revenue rose 57% year over year to $72.9 million, beating estimates, while its loss of $0.03 per share was narrower than expected. The company also raised its 2026 revenue guidance to $262 million–$264 million, above consensus.

Heartflow (NASDAQ:HTFL - Get Free Report) had its target price lifted by stock analysts at Canaccord Genuity Group from $56.00 to $69.00 in a report released on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's price objective indicates a potential upside of 15.15% from the stock's previous close.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Heartflow from a "buy" rating to a "hold" rating in a report on Saturday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Heartflow from $35.00 to $45.00 and gave the company an "overweight" rating in a report on Friday, August 14th. Piper Sandler reiterated an "overweight" rating and set a $64.00 price objective (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. Morgan Stanley increased their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company an "equal weight" rating in a research note on Friday, August 14th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Heartflow in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $56.25.

Heartflow Stock Performance

Heartflow stock opened at $59.92 on Friday. The stock has a fifty day moving average of $51.93 and a 200-day moving average of $35.14. The stock has a market capitalization of $5.21 billion, a P/E ratio of -32.74 and a beta of 2.50. Heartflow has a 52 week low of $20.13 and a 52 week high of $60.65.

Heartflow (NASDAQ:HTFL - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The firm had revenue of $72.86 million for the quarter. During the same quarter in the prior year, the firm earned ($0.27) EPS. On average, research analysts forecast that Heartflow will post -0.75 earnings per share for the current year.

Insider Activity

In other news, CEO John Farquhar sold 38,900 shares of Heartflow stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $55.74, for a total transaction of $2,168,286.00. Following the transaction, the chief executive officer owned 251,983 shares in the company, valued at approximately $14,045,532.42. The trade was a 13.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Campbell Rogers sold 23,933 shares of Heartflow stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $55.01, for a total transaction of $1,316,554.33. Following the transaction, the insider owned 73,453 shares in the company, valued at approximately $4,040,649.53. This trade represents a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 332,403 shares of company stock valued at $16,602,786. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Heartflow

A number of institutional investors and hedge funds have recently bought and sold shares of HTFL. XXEC Inc. bought a new position in Heartflow during the second quarter worth $2,524,764,000. Quantinno Capital Management LP acquired a new position in Heartflow in the first quarter valued at $1,734,000. Sei Investments Co. boosted its position in Heartflow by 342.5% during the first quarter. Sei Investments Co. now owns 67,048 shares of the company's stock valued at $1,631,000 after acquiring an additional 51,895 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Heartflow during the second quarter valued at $19,096,000. Finally, Handelsbanken Fonder AB acquired a new stake in Heartflow during the 2nd quarter worth about $910,000.

Recent Heartflow Headlines

These are some of the HTFL headlines that stood out recently:

• Positive Sentiment: Third-quarter revenue rose 57% year over year to $72.9 million, exceeding the roughly $65.2 million analyst estimate. The loss was $0.03 per share, narrower than both the expected $0.18 loss and the $0.27 loss a year earlier. HeartFlow Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.6 million consensus estimate. The higher outlook may signal stronger growth expectations. Heartflow Expects 2026 Revenue of $262M–$264M
• Negative Sentiment: CEO insider selling may weigh on sentiment: the CEO sold $2.17 million of Heartflow stock. A sale by itself does not establish the reason for the transaction. Heartflow CEO Sells $2.17 Million in Stock

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient's coronary arteries and provide information that can support diagnosis and treatment planning. The company's offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.